Cancer
04/10/2002
By David Loshak
Patients with fludarabine-refractory chronic lymphocytic leukaemia and small cell lymphocytic lymphoma often suffer serious infections which could make a significant difference in interpreting clinical trials of new and highly effective agents.
Investigators at the Walter Reed Army Medical Center, Washington D.C. and Ohio State University, Columbus, Ohio, United States, suggest that the incidence of serious infections after treatment in trials with new agents might, in light of their findings, no longer seem too high.
The investigators pointed out that not only were treatments for fludarabine-refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma limited, but also that most new treatments being examined in fludarabine-refractory patients led to high rates of serious infection. Moreover, there were few data about the frequency of infections in these patients when they received non-investigational best supportive care.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!